<?xml version="1.0" encoding="utf-8"?>
<iati-activities xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" version="2.03" generated-datetime="2026-02-14T15:39:51.3060117+01:00" linked-data-default="http://data-service.theglobalfund.org/api">
	<iati-activity last-updated-datetime="2026-02-14T00:00:00+01:00" xml:lang="en" default-currency="USD" humanitarian="false" hierarchy="1">
		<iati-identifier>47045-AFG-Z-UNDP-2</iati-identifier>
		<reporting-org ref="47045" type="30" secondary-reporter="false">
			<narrative xml:lang="en">The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
		</reporting-org>
		<title>
			<narrative xml:lang="en">Combined grant to support HIV/AIDS, Tuberculosis &amp; Malaria programs and Health Systems in Afghanistan - Afghanistan (01-Jan-2024-31-Dec-2026)</narrative>
		</title>
		<description type="1">
			<narrative xml:lang="en">Afghanistan, Multicomponent, United Nations Development Programme (UNDP Afghanistan)This program has the following goals: To ensure that Afghanistan is on track to reduce the malaria burden by 95% by 2030 and eliminate malaria by 2035 – contributing towards country development and the Sustainable Development Goals..  The goal of the NSP is to halt new HIV, STI &amp; Hepatitis infections and improve the health and quality of life for people living with and affected by HIV, STIs, and Hepatitis in Afghanistan by 2026..  To reduce TB deaths by 75% by the end of 2026 compared to 2015.  To decrease the incidence rate by 20% by 2026 (to reach a 10/100,000 by 2035)   in order to be aligned with the End TB Strategy.  To improve the quality of services and increase effectiveness of HTM and Strengthen the Health Systems.. The objectives of this program are: To reduce the number of category 1 and cat 2 districts by at least 50% in 2026. It means, as a result, that a total of 42 districts are expected to be classified in cat 1 and 2 in 2026. It equally means as a result that the malaria burden in those 84 districts will be reduced by approx. 50% in 2026 against baseline data from 2019 to 2021.  To interrupt indigenous transmission of malaria by 2026 in 20% of the 237 districts categorized in cat 3. It means interrupting local transmission in at least 47 cat 3 districts by 2026.  To prevent the re-establishment of local malaria transmission in cat 4 districts and communities where the disease has been eliminated during the last 3 years. It means keeping the 77 districts classified cat 4 free of local malaria transmission by 2026.  To enhance and access of a continuum of high quality essential services for HIV, STIs and Hepatitis to maintain prevalence of HIV below 5% among key populations, less than 0.1% among general population and reduce the incidence of Hepatitis B &amp; C by 60%.  To enhance strategic information systems for HIV, STI and hepatitis for informed policy and decision making and evidenced-based response.  To enhance Policy environment and ANPASH responsiveness for continuum of high quality essential services support for HIV, STIs and Hepatitis.  To increase the case notification of all TB cases by 8% every year.  To detect and treat at least 30% of the estimated DR-TB cases by 2026.  To detect and treat at least 50% of the estimated latent TB cases by 2026.  To ensure no affected families face catastrophic costs due to tuberculosis.  Focus on the key health systems functions for HTM &amp; pandemic preparedness to accelerate impact (community, lab, data, supply chain, and health financing systems, harnessing the private sector) to facilitate integrated, people-centered quality services..  Strengthen measurement of RSSH to assess results, contributions to HTM &amp; pandemic preparedness (PP), as well as HTM contributions to systems.</narrative>
		</description>
		<participating-org ref="47045" type="30" role="1">
			<narrative xml:lang="en">The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
		</participating-org>
		<participating-org ref="47045" type="30" role="1">
			<narrative xml:lang="en">The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
		</participating-org>
		<participating-org type="40" role="2">
			<narrative xml:lang="en">United Nations Development Programme</narrative>
		</participating-org>
		<participating-org type="40" role="3">
			<narrative xml:lang="en">United Nations Development Programme</narrative>
		</participating-org>
		<participating-org type="40" role="4">
			<narrative xml:lang="en">United Nations Development Programme</narrative>
		</participating-org>
		<other-identifier ref="AFG-Z-UNDPP02" type="A1">
			<owner-org ref="47045">
				<narrative xml:lang="en">The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
			</owner-org>
		</other-identifier>
		<activity-status code="2" />
		<activity-date type="1" iso-date="2024-01-01" />
		<activity-date type="2" iso-date="2024-01-01" />
		<activity-date type="3" iso-date="2026-12-31" />
		<contact-info type="1">
			<organisation>
				<narrative xml:lang="en">The Global Fund to Fight AIDS Tuberculosis and Malaria</narrative>
			</organisation>
			<department>
				<narrative xml:lang="en">Communications</narrative>
			</department>
			<person-name>
				<narrative xml:lang="en">Web Team</narrative>
			</person-name>
			<job-title>
				<narrative xml:lang="en"> </narrative>
			</job-title>
			<telephone>+41 58 791 1700</telephone>
			<email>website@theglobalfund.org</email>
			<website>https://www.theglobalfund.org</website>
			<mailing-address>
				<narrative xml:lang="en">The Global Fund to Fight AIDS, Tuberculosis and Malaria, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland</narrative>
			</mailing-address>
		</contact-info>
		<contact-info type="2">
			<organisation>
				<narrative xml:lang="en">The Global Fund to Fight AIDS Tuberculosis and Malaria</narrative>
			</organisation>
			<department>
				<narrative xml:lang="en">Grant Management Division</narrative>
			</department>
			<person-name>
				<narrative xml:lang="en">Olivier, CAVEY</narrative>
			</person-name>
			<job-title>
				<narrative xml:lang="en">Fund Portfolio Manager</narrative>
			</job-title>
			<telephone>+41 58 791 1700</telephone>
			<email>olivier.cavey@theglobalfund.org</email>
			<website>https://www.theglobalfund.org</website>
			<mailing-address>
				<narrative xml:lang="en">The Global Fund to Fight AIDS, Tuberculosis and Malaria, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland</narrative>
			</mailing-address>
		</contact-info>
		<contact-info type="4">
			<organisation>
				<narrative xml:lang="en">The Global Fund to Fight AIDS Tuberculosis and Malaria</narrative>
			</organisation>
			<department>
				<narrative xml:lang="en">Communications</narrative>
			</department>
			<person-name>
				<narrative xml:lang="en">Web Team</narrative>
			</person-name>
			<telephone>+41 58 791 1700</telephone>
			<email>website@theglobalfund.org</email>
			<website>https://www.theglobalfund.org</website>
			<mailing-address>
				<narrative xml:lang="en">The Global Fund to Fight AIDS, Tuberculosis and Malaria, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland</narrative>
			</mailing-address>
		</contact-info>
		<activity-scope code="4" />
		<recipient-country code="AF" percentage="100">
			<narrative xml:lang="en">Afghanistan</narrative>
		</recipient-country>
		<sector vocabulary="1" code="13040" percentage="8">
			<narrative xml:lang="en">HIV</narrative>
		</sector>
		<sector vocabulary="1" code="12262" percentage="20">
			<narrative xml:lang="en">Malaria</narrative>
		</sector>
		<sector vocabulary="1" code="12110" percentage="32">
			<narrative xml:lang="en">Multicomponent</narrative>
		</sector>
		<sector vocabulary="1" code="12110" percentage="6">
			<narrative xml:lang="en">RSSH</narrative>
		</sector>
		<sector vocabulary="1" code="12263" percentage="34">
			<narrative xml:lang="en">Tuberculosis</narrative>
		</sector>
		<country-budget-items vocabulary="4">
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">HIV -&gt; Differentiated HIV Testing Services -&gt; Community-based testing for KP programs</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">HIV -&gt; Differentiated HIV Testing Services -&gt; Facility-based testing for adolescent girls and young women (AGYW) and their male sexual partners programs</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">HIV -&gt; Differentiated HIV Testing Services -&gt; Facility-based testing for key population (KP) programs</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">HIV -&gt; Prevention package for people in prisons and other closed settings -&gt; Condom and lubricant programing for prisoners</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="1">
				<description>
					<narrative xml:lang="en">HIV -&gt; Prevention package for people in prisons and other closed settings -&gt; Harm reduction interventions for drug use for prisoners</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">HIV -&gt; Prevention package for people in prisons and other closed settings -&gt; Sexual and reproductive health services, including STIs, hepatitis, post-violence care for prisoners</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">HIV -&gt; Prevention package for people who use drugs (PUD) and their sexual partners -&gt; Community empowerment for PUD</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">HIV -&gt; Prevention package for people who use drugs (PUD) and their sexual partners -&gt; Condom and lubricant programing for PUD</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">HIV -&gt; Prevention package for people who use drugs (PUD) and their sexual partners -&gt; HIV prevention communication, information and demand creation for PUD</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="3">
				<description>
					<narrative xml:lang="en">HIV -&gt; Prevention package for people who use drugs (PUD) and their sexual partners -&gt; Needle and syringe programs for PWID</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="1">
				<description>
					<narrative xml:lang="en">HIV -&gt; Prevention package for people who use drugs (PUD) and their sexual partners -&gt; Opioid substitution therapy and other medically assisted drug dependence treatment for PWID</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="1">
				<description>
					<narrative xml:lang="en">HIV -&gt; Prevention package for people who use drugs (PUD) and their sexual partners -&gt; Sexual and reproductive health services, including STIs, hepatitis, post-violence care for PUD</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">HIV -&gt; Reducing human rights-related barriers to HIV/TB services -&gt; Eliminating stigma and discrimination in all settings</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">HIV -&gt; Reducing human rights-related barriers to HIV/TB services -&gt; Improving laws, regulations and polices relating to HIV and HIV/TB</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="1">
				<description>
					<narrative xml:lang="en">HIV -&gt; Treatment, care and support -&gt; HIV treatment and differentiated service delivery - adults (15 and above)</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">HIV -&gt; Treatment, care and support -&gt; HIV treatment and differentiated service delivery - children (under 15)</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">HIV -&gt; Treatment, care and support -&gt; Integrated management of common co-infections and co-morbidities (adults and children)</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">HIV -&gt; Treatment, care and support -&gt; Treatment monitoring - Viral load and antiretroviral (ARV) toxicity</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">Malaria -&gt; Case management -&gt; Epidemic preparedness</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">Malaria -&gt; Case management -&gt; Facility-based treatment</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">Malaria -&gt; Case management -&gt; Integrated community case management (iCCM)</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">Malaria -&gt; Case management -&gt; Private sector case management</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">Malaria -&gt; Case management -&gt; Therapeutic efficacy surveillance</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">Malaria -&gt; Vector control -&gt; Entomological monitoring</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="1">
				<description>
					<narrative xml:lang="en">Malaria -&gt; Vector control -&gt; Indoor residual spraying (IRS)</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="3">
				<description>
					<narrative xml:lang="en">Malaria -&gt; Vector control -&gt; Insecticide treated nets (ITNs) - Continuous distribution: ANC</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="15">
				<description>
					<narrative xml:lang="en">Malaria -&gt; Vector control -&gt; Insecticide treated nets (ITNs) - Mass campaign: universal</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="9">
				<description>
					<narrative xml:lang="en">Multicomponent -&gt; Program management -&gt; Coordination and management of national disease control programs</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="23">
				<description>
					<narrative xml:lang="en">Multicomponent -&gt; Program management -&gt; Grant management</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">RSSH -&gt; RSSH: Health products management systems -&gt; Regulatory/quality assurance support</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">RSSH -&gt; RSSH: Health products management systems -&gt; Storage and distribution capacity, design &amp; operations</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="1">
				<description>
					<narrative xml:lang="en">RSSH -&gt; RSSH: Monitoring and evaluation systems -&gt; Analyses, evaluations, reviews and data use</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">RSSH -&gt; RSSH: Monitoring and evaluation systems -&gt; Routine reporting</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">RSSH -&gt; RSSH: Monitoring and evaluation systems -&gt; Surveillance for HIV, tuberculosis and malaria</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">RSSH -&gt; RSSH/PP: Human resources for health (HRH) and quality of care -&gt; RSSH/PP: Community health workers: contracting, remuneration and retention</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="1">
				<description>
					<narrative xml:lang="en">RSSH -&gt; RSSH/PP: Human resources for health (HRH) and quality of care -&gt; RSSH/PP: HRH planning, management and governance including for community health workers (CHWs)</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">RSSH -&gt; RSSH/PP: Human resources for health (HRH) and quality of care -&gt; RSSH/PP: In-service training (excluding community health workers)</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="1">
				<description>
					<narrative xml:lang="en">RSSH -&gt; RSSH/PP: Human resources for health (HRH) and quality of care -&gt; RSSH/PP: Integrated supportive supervision for health workers (excluding CHWs)</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">RSSH -&gt; RSSH/PP: Human resources for health (HRH) and quality of care -&gt; RSSH/PP: Quality improvement and capacity building for quality of care</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">RSSH -&gt; RSSH/PP: Laboratory systems (including national and peripheral) -&gt; RSSH/PP: Laboratory Information systems</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="4">
				<description>
					<narrative xml:lang="en">RSSH -&gt; RSSH/PP: Laboratory systems (including national and peripheral) -&gt; RSSH/PP: Laboratory-based surveillance</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">Tuberculosis -&gt; Collaboration with other providers and sectors -&gt; Private provider engagement in TB/DR-TB care</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="5">
				<description>
					<narrative xml:lang="en">Tuberculosis -&gt; Drug-resistant (DR)-TB diagnosis, treatment and care -&gt; DR-TB diagnosis/drug susceptibility testing (DST)</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="3">
				<description>
					<narrative xml:lang="en">Tuberculosis -&gt; Drug-resistant (DR)-TB diagnosis, treatment and care -&gt; DR-TB treatment, care and support</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="3">
				<description>
					<narrative xml:lang="en">Tuberculosis -&gt; Key and vulnerable populations (KVP) - TB/DR-TB -&gt; KVP - Children and adolescents</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="2">
				<description>
					<narrative xml:lang="en">Tuberculosis -&gt; Key and vulnerable populations (KVP) - TB/DR-TB -&gt; KVP - Mobile population (migrants/refugees/IDPs)</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">Tuberculosis -&gt; Key and vulnerable populations (KVP) - TB/DR-TB -&gt; KVP - People in prisons/jails/detention centers</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">Tuberculosis -&gt; Removing human rights and gender related barriers to TB services -&gt; Eliminating TB-related stigma and discrimination</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="12">
				<description>
					<narrative xml:lang="en">Tuberculosis -&gt; TB diagnosis, treatment and care -&gt; TB screening and diagnosis</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="9">
				<description>
					<narrative xml:lang="en">Tuberculosis -&gt; TB diagnosis, treatment and care -&gt; TB treatment, care and support</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="1">
				<description>
					<narrative xml:lang="en">Tuberculosis -&gt; TB/DR-TB Prevention -&gt; Screening/testing for TB infection</narrative>
				</description>
			</budget-item>
		</country-budget-items>
		<collaboration-type code="1" />
		<default-flow-type code="10" />
		<default-finance-type code="110" />
		<default-aid-type code="C01" />
		<default-tied-status code="5" />
		<budget type="2" status="2">
			<period-start iso-date="2024-01-01" />
			<period-end iso-date="2024-12-31" />
			<value currency="USD" value-date="2024-01-01">14711675.57</value>
		</budget>
		<budget type="2" status="2">
			<period-start iso-date="2025-01-01" />
			<period-end iso-date="2025-12-31" />
			<value currency="USD" value-date="2024-01-01">26979010.90</value>
		</budget>
		<budget type="2" status="2">
			<period-start iso-date="2026-01-01" />
			<period-end iso-date="2026-12-31" />
			<value currency="USD" value-date="2024-01-01">21512359.48</value>
		</budget>
		<transaction ref="f361e346-d8e6-4dd8-b727-b28c8dbaf7e7">
			<transaction-type code="2" />
			<transaction-date iso-date="2025-07-30" />
			<value currency="USD" value-date="2025-07-30">4929422.00</value>
			<description>
				<narrative xml:lang="en">Global Fund Commitment to AFG-Z-UNDPP02.</narrative>
			</description>
			<provider-org type="40">
				<narrative xml:lang="en">Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
			</provider-org>
			<receiver-org>
				<narrative xml:lang="en">United Nations Development Programme (UNDP Afghanistan)</narrative>
			</receiver-org>
			<aid-type code="C01" />
			<tied-status code="5" />
		</transaction>
		<transaction ref="4c6f46c4-8b81-4fe1-8b65-c547e0be3138">
			<transaction-type code="2" />
			<transaction-date iso-date="2023-11-02" />
			<value currency="USD" value-date="2023-11-02">37240975.48</value>
			<description>
				<narrative xml:lang="en">Global Fund Commitment to AFG-Z-UNDPP02.</narrative>
			</description>
			<provider-org type="40">
				<narrative xml:lang="en">Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
			</provider-org>
			<receiver-org>
				<narrative xml:lang="en">United Nations Development Programme (UNDP Afghanistan)</narrative>
			</receiver-org>
			<aid-type code="C01" />
			<tied-status code="5" />
		</transaction>
		<transaction ref="9433c5b1-d521-43ce-879c-4f0bbe3831d6">
			<transaction-type code="2" />
			<transaction-date iso-date="2025-05-31" />
			<value currency="USD" value-date="2025-05-31">3029021.00</value>
			<description>
				<narrative xml:lang="en">Global Fund Commitment to AFG-Z-UNDPP02.</narrative>
			</description>
			<provider-org type="40">
				<narrative xml:lang="en">Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
			</provider-org>
			<receiver-org>
				<narrative xml:lang="en">United Nations Development Programme (UNDP Afghanistan)</narrative>
			</receiver-org>
			<aid-type code="C01" />
			<tied-status code="5" />
		</transaction>
		<transaction ref="1e0e9a9a-5094-4e0c-ade3-212d4491cb3f">
			<transaction-type code="2" />
			<transaction-date iso-date="2025-11-20" />
			<value currency="USD" value-date="2025-11-20">14718365.52</value>
			<description>
				<narrative xml:lang="en">Global Fund Commitment to AFG-Z-UNDPP02.</narrative>
			</description>
			<provider-org type="40">
				<narrative xml:lang="en">Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
			</provider-org>
			<receiver-org>
				<narrative xml:lang="en">United Nations Development Programme (UNDP Afghanistan)</narrative>
			</receiver-org>
			<aid-type code="C01" />
			<tied-status code="5" />
		</transaction>
		<transaction ref="fca8684f-9564-475b-8276-8fee6ae7b2f8">
			<transaction-type code="3" />
			<transaction-date iso-date="2025-11-25" />
			<value currency="USD" value-date="2025-11-25">1772393.00</value>
			<description>
				<narrative xml:lang="en">Global Fund disbursement to AFG-Z-UNDPP02.</narrative>
			</description>
			<provider-org type="40">
				<narrative xml:lang="en">Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
			</provider-org>
			<receiver-org>
				<narrative xml:lang="en">United Nations Development Programme (UNDP Afghanistan)</narrative>
			</receiver-org>
			<aid-type code="C01" />
			<tied-status code="5" />
		</transaction>
		<transaction ref="2d6c0c28-4306-453b-b274-95a6b9c98f81">
			<transaction-type code="3" />
			<transaction-date iso-date="2024-01-04" />
			<value currency="USD" value-date="2024-01-04">8764614.00</value>
			<description>
				<narrative xml:lang="en">Global Fund disbursement to AFG-Z-UNDPP02.</narrative>
			</description>
			<provider-org type="40">
				<narrative xml:lang="en">Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
			</provider-org>
			<receiver-org>
				<narrative xml:lang="en">United Nations Development Programme (UNDP Afghanistan)</narrative>
			</receiver-org>
			<aid-type code="C01" />
			<tied-status code="5" />
		</transaction>
		<transaction ref="8a0e6e77-a350-4626-beea-e2f448d19f1c">
			<transaction-type code="3" />
			<transaction-date iso-date="2024-12-18" />
			<value currency="USD" value-date="2024-12-18">4936254.48</value>
			<description>
				<narrative xml:lang="en">Global Fund disbursement to AFG-Z-UNDPP02.</narrative>
			</description>
			<provider-org type="40">
				<narrative xml:lang="en">Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
			</provider-org>
			<receiver-org>
				<narrative xml:lang="en">United Nations Development Programme (UNDP Afghanistan)</narrative>
			</receiver-org>
			<aid-type code="C01" />
			<tied-status code="5" />
		</transaction>
		<transaction ref="caa43367-ed66-41a9-a3ed-3cc49fb063ce">
			<transaction-type code="3" />
			<transaction-date iso-date="2024-06-11" />
			<value currency="USD" value-date="2024-06-11">20083880.00</value>
			<description>
				<narrative xml:lang="en">Global Fund disbursement to AFG-Z-UNDPP02.</narrative>
			</description>
			<provider-org type="40">
				<narrative xml:lang="en">Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
			</provider-org>
			<receiver-org>
				<narrative xml:lang="en">United Nations Development Programme (UNDP Afghanistan)</narrative>
			</receiver-org>
			<aid-type code="C01" />
			<tied-status code="5" />
		</transaction>
		<transaction ref="7cf0948d-f69b-4154-a4f4-fc8e564c730c">
			<transaction-type code="3" />
			<transaction-date iso-date="2025-11-25" />
			<value currency="USD" value-date="2025-11-25">894542.00</value>
			<description>
				<narrative xml:lang="en">Global Fund disbursement to AFG-Z-UNDPP02.</narrative>
			</description>
			<provider-org type="40">
				<narrative xml:lang="en">Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
			</provider-org>
			<receiver-org>
				<narrative xml:lang="en">United Nations Development Programme (UNDP Afghanistan)</narrative>
			</receiver-org>
			<aid-type code="C01" />
			<tied-status code="5" />
		</transaction>
		<transaction ref="9d359746-6fda-43f8-b0b0-55e44cfa40ee">
			<transaction-type code="3" />
			<transaction-date iso-date="2025-06-03" />
			<value currency="USD" value-date="2025-06-03">3029021.00</value>
			<description>
				<narrative xml:lang="en">Global Fund disbursement to AFG-Z-UNDPP02.</narrative>
			</description>
			<provider-org type="40">
				<narrative xml:lang="en">Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
			</provider-org>
			<receiver-org>
				<narrative xml:lang="en">United Nations Development Programme (UNDP Afghanistan)</narrative>
			</receiver-org>
			<aid-type code="C01" />
			<tied-status code="5" />
		</transaction>
		<transaction ref="2a0490fe-b422-4b29-8ead-4991bdddbf1e">
			<transaction-type code="3" />
			<transaction-date iso-date="2025-08-05" />
			<value currency="USD" value-date="2025-08-05">4929422.00</value>
			<description>
				<narrative xml:lang="en">Global Fund disbursement to AFG-Z-UNDPP02.</narrative>
			</description>
			<provider-org type="40">
				<narrative xml:lang="en">Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
			</provider-org>
			<receiver-org>
				<narrative xml:lang="en">United Nations Development Programme (UNDP Afghanistan)</narrative>
			</receiver-org>
			<aid-type code="C01" />
			<tied-status code="5" />
		</transaction>
		<transaction ref="4a48796b-6beb-42e1-b62b-c0cd80406238">
			<transaction-type code="3" />
			<transaction-date iso-date="2024-10-22" />
			<value currency="USD" value-date="2024-10-22">3456227.00</value>
			<description>
				<narrative xml:lang="en">Global Fund disbursement to AFG-Z-UNDPP02.</narrative>
			</description>
			<provider-org type="40">
				<narrative xml:lang="en">Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
			</provider-org>
			<receiver-org>
				<narrative xml:lang="en">United Nations Development Programme (UNDP Afghanistan)</narrative>
			</receiver-org>
			<aid-type code="C01" />
			<tied-status code="5" />
		</transaction>
		<document-link url="https://data.theglobalfund.org/grant/AFG-Z-UNDP" format="text/html">
			<title>
				<narrative xml:lang="en">Grant page on the data portal of the Global Fund.</narrative>
			</title>
			<description>
				<narrative xml:lang="en">An overview of a grant over it's lifetime.</narrative>
			</description>
			<category code="A12" />
			<category code="A02" />
			<category code="A01" />
			<category code="A07" />
			<category code="A05" />
			<category code="A08" />
			<document-date iso-date="2026-02-14" />
		</document-link>
		<document-link url="https://www.theglobalfund.org/media/13342/core_grantregulationsversiontwo_regulations_en.pdf" format="application/pdf">
			<title>
				<narrative xml:lang="en">Grant terms and conditions.</narrative>
			</title>
			<description>
				<narrative xml:lang="en">General terms and conditions which apply to Global Fund grants.</narrative>
			</description>
			<category code="A04" />
			<document-date iso-date="2026-02-14" />
		</document-link>
		<result type="1" aggregation-status="false">
			<title>
				<narrative xml:lang="en">Coverage / Output indicators targets and results for AFG-Z-UNDPP02</narrative>
			</title>
			<indicator measure="1" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Number of people in prisons and other closed settings reached with HIV prevention programs - defined package of services</narrative>
				</title>
				<period>
					<period-start iso-date="2024-01-01" />
					<period-end iso-date="2024-06-30" />
					<target value="13531" />
					<actual value="6541" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Percentage of people who inject drugs that have received an HIV test during the reporting period in KP-specific programs and know their results</narrative>
				</title>
				<period>
					<period-start iso-date="2024-01-01" />
					<period-end iso-date="2024-06-30" />
					<target value="70.89" />
					<actual value="51.04" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Percentage of notified patients with all forms of TB (i.e., bacteriologically confirmed + clinically diagnosed) contributed by non-national TB program providers- community referrals; *includes only those with new and relapse TB</narrative>
				</title>
				<period>
					<period-start iso-date="2024-01-01" />
					<period-end iso-date="2024-06-30" />
					<target value="14.66" />
					<actual value="16.70" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Proportion of confirmed malaria cases that received first-line antimalarial treatment at public sector health facilities</narrative>
				</title>
				<period>
					<period-start iso-date="2024-01-01" />
					<period-end iso-date="2024-06-30" />
					<target value="99.00" />
					<actual value="99.26" />
				</period>
			</indicator>
			<indicator measure="1" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Number of insecticide-treated nets distributed to populations at risk of malaria transmission through mass campaigns</narrative>
				</title>
				<period>
					<period-start iso-date="2024-01-01" />
					<period-end iso-date="2024-06-30" />
					<target value="43333" />
					<actual value="10105" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Percentage of people who inject drugs reached with HIV prevention programs - defined package of services</narrative>
				</title>
				<period>
					<period-start iso-date="2024-01-01" />
					<period-end iso-date="2024-06-30" />
					<target value="78.77" />
					<actual value="63.62" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Percentage of individuals receiving Opioid Substitution Therapy who received treatment for at least 6 months</narrative>
				</title>
				<period>
					<period-start iso-date="2024-01-01" />
					<period-end iso-date="2024-06-30" />
					<target value="90.21" />
					<actual value="49.40" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Percentage of people on ART among all people living with HIV at the end of the reporting period</narrative>
				</title>
				<period>
					<period-start iso-date="2024-01-01" />
					<period-end iso-date="2024-06-30" />
					<target value="12.40" />
					<actual value="10.87" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Percentage of districts achieving national target for the proportion of confirmed malaria patients who received first-line antimalarial treatment</narrative>
				</title>
				<period>
					<period-start iso-date="2024-01-01" />
					<period-end iso-date="2024-06-30" />
					<target value="84.00" />
					<actual value="82.69" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Proportion of confirmed malaria cases that received first-line antimalarial treatment in the community</narrative>
				</title>
				<period>
					<period-start iso-date="2024-01-01" />
					<period-end iso-date="2024-06-30" />
					<target value="97.50" />
					<actual value="96.66" />
				</period>
			</indicator>
			<indicator measure="1" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Number of insecticide-treated nets distributed to targeted risk groups through continuous distribution</narrative>
				</title>
				<period>
					<period-start iso-date="2024-01-01" />
					<period-end iso-date="2024-06-30" />
					<target value="120057" />
					<actual value="94049" />
				</period>
			</indicator>
			<indicator measure="1" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Number of people with confirmed RR-TB and/or MDR-TB notified</narrative>
				</title>
				<period>
					<period-start iso-date="2024-01-01" />
					<period-end iso-date="2024-06-30" />
					<target value="543" />
					<actual value="237" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Proportion of suspected malaria cases that receive a parasitological test in the community</narrative>
				</title>
				<period>
					<period-start iso-date="2024-01-01" />
					<period-end iso-date="2024-06-30" />
					<target value="99.99" />
					<actual value="99.99" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Treatment success rate- all forms: Percentage of patients with all forms of TB, bacteriologically confirmed plus clinically diagnosed, successfully treated (cured plus treatment completed) among all TB patients notified during a specified period; *includes only those with new and relapse TB</narrative>
				</title>
				<period>
					<period-start iso-date="2024-01-01" />
					<period-end iso-date="2024-06-30" />
					<target value="90.00" />
					<actual value="94.54" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Timeliness of reporting: Percentage of submitted monthly reports (for the reporting period) that are received on time per the national guidelines</narrative>
				</title>
				<period>
					<period-start iso-date="2024-01-01" />
					<period-end iso-date="2024-06-30" />
					<target value="90.00" />
					<actual value="100.00" />
				</period>
			</indicator>
			<indicator measure="1" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Number of patients with of all forms of TB notified (i.e., bacteriologically confirmed + clinically diagnosed); *includes only those with new and relapse TB</narrative>
				</title>
				<period>
					<period-start iso-date="2024-01-01" />
					<period-end iso-date="2024-06-30" />
					<target value="33640" />
					<actual value="25767" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Percentage of other vulnerable populations that have received an HIV test during the reporting period and know their results</narrative>
				</title>
				<period>
					<period-start iso-date="2024-01-01" />
					<period-end iso-date="2024-06-30" />
					<target value="10400" />
					<actual value="0.00" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Percentage of people living with HIV currently enrolled on antiretroviral therapy who started TB preventive treatment (TPT) during the reporting period</narrative>
				</title>
				<period>
					<period-start iso-date="2024-01-01" />
					<period-end iso-date="2024-06-30" />
					<target value="38.00" />
					<actual value="43.56" />
				</period>
			</indicator>
			<indicator measure="1" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Number of people in prisons and other closed settings that have received an HIV test during the reporting period and know their results</narrative>
				</title>
				<period>
					<period-start iso-date="2024-01-01" />
					<period-end iso-date="2024-06-30" />
					<target value="12177" />
					<actual value="4978" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Proportion of suspected malaria cases that receive a parasitological test at public sector health facilities</narrative>
				</title>
				<period>
					<period-start iso-date="2024-01-01" />
					<period-end iso-date="2024-06-30" />
					<target value="99.98" />
					<actual value="99.93" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Percentage of laboratories successfully participating in external quality assurance (EQA) or proficiency testing (PT) schemes</narrative>
				</title>
				<period>
					<period-start iso-date="2024-01-01" />
					<period-end iso-date="2024-06-30" />
					<target value="100.00" />
					<actual value="85.71" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Treatment success rate of RR-TB and/or MDR-TB: Percentage of patients with RR and/or MDR-TB successfully treated</narrative>
				</title>
				<period>
					<period-start iso-date="2024-01-01" />
					<period-end iso-date="2024-06-30" />
					<target value="65.00" />
					<actual value="64.03" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Percentage of notified patients with all forms of TB (i.e., bacteriologically confirmed + clinically diagnosed) contributed by non-national TB program providers- private/non-governmental facilities; *includes only those with new and relapse TB</narrative>
				</title>
				<period>
					<period-start iso-date="2024-01-01" />
					<period-end iso-date="2024-06-30" />
					<target value="12.80" />
					<actual value="14.53" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Percentage of new and relapse TB patients tested using WHO recommended rapid diagnostic tests at the time of diagnosis</narrative>
				</title>
				<period>
					<period-start iso-date="2024-01-01" />
					<period-end iso-date="2024-06-30" />
					<target value="55.00" />
					<actual value="57.69" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Percentage of people with confirmed RR-TB and/or MDR-TB that began second-line treatment</narrative>
				</title>
				<period>
					<period-start iso-date="2024-01-01" />
					<period-end iso-date="2024-06-30" />
					<target value="95.96" />
					<actual value="99.16" />
				</period>
			</indicator>
			<indicator measure="1" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Number of people with TB (all forms) notified among key affected populations/high risk groups (other than prisoners); *includes only those with new and relapse</narrative>
				</title>
				<period>
					<period-start iso-date="2024-01-01" />
					<period-end iso-date="2024-06-30" />
					<target value="672" />
					<actual value="621" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Percentage of districts achieving national target for the proportion of suspected malaria patients who receive a parasitological test</narrative>
				</title>
				<period>
					<period-start iso-date="2024-01-01" />
					<period-end iso-date="2024-06-30" />
					<target value="100.00" />
					<actual value="98.08" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Completeness of reporting: Percentage of expected monthly reports (for the reporting period) that are actually received</narrative>
				</title>
				<period>
					<period-start iso-date="2024-01-01" />
					<period-end iso-date="2024-06-30" />
					<target value="90.00" />
					<actual value="85.76" />
				</period>
			</indicator>
			<indicator measure="1" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Number of people in contact with TB patients who began preventive therapy</narrative>
				</title>
				<period>
					<period-start iso-date="2024-01-01" />
					<period-end iso-date="2024-06-30" />
					<target value="31815" />
					<actual value="16501" />
				</period>
			</indicator>
		</result>
	</iati-activity>
	<iati-activity last-updated-datetime="2026-02-14T00:00:00+01:00" xml:lang="en" default-currency="USD" humanitarian="false" hierarchy="1">
		<iati-identifier>47045-AFG-Z-UNDP-1</iati-identifier>
		<reporting-org ref="47045" type="30" secondary-reporter="false">
			<narrative xml:lang="en">The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
		</reporting-org>
		<title>
			<narrative xml:lang="en">Combined grant to support HIV/AIDS, Tuberculosis &amp; Malaria programs and Health Systems in Afghanistan - Afghanistan (01-Oct-2021-31-Dec-2023)</narrative>
		</title>
		<description type="1">
			<narrative xml:lang="en">Afghanistan, Multicomponent, United Nations Development Programme (UNDP Afghanistan)This program has the following goals: The goal of the NSP IV is to halt new HIV, STI &amp; Hepatitis infections and improve the health and quality of life of people living with and affected by HIV, STIs, and Hepatitis in Afghanistan over the next five years..  To reduce TB deaths by 75% by the end of 2025 compared to 2015.  To ensure that Afghanistan is on track to eliminate malaria by 2030 – contributing towards country development and the Sustainable Development Goals.  To decrease TB incidence rate by 20% by 2024 (to reach 50% reduction in incidence rate compared to 2015) in order to be aligned with End TB Strategy.  To strengthen the health system to reduce mortality and morbidity associated with ATM and RMNCH. The objectives of this program are: To focus strategically on prevention services for HIV and other infections for key populations (PWID, prisoners and other vulnerable populations).  To increase the case notification of all TB cases at least 12% annually until 2023 and maintain full coverage thereafter, and to sustain treatment success rate, at least, 90% by 2025.  Reducing the reported malaria incidence by 73% at the national level compared with 2016.  To increase the coverage and quality of opiod substitution therapy for people who inject drugs by 2023.  To detect and treat at least 80% of estimated MDR-TB cases by 2025.  Interrupting indigenous transmission of malaria in 23 Provinces (Badghis, Baghlan, Farah, Ghor, Hirat, Jawzjan, Kabul, Kunduz, Nimroz, Parwan, Samangan, Balkh, Bamyan, Dykundi, Kapisa, Panjsher, Sar-e-Pul, Takhar, Urozgan, Badakhshan, Faryab, Logar and Zabul) by 2022.  To increase the coverage and quality of antiretroviral therapy services for people living with HIV by 2023.  To detect and treat at least 50% of the estimated latent TB cases as the accumulation by 2025.  Preventing the re-establishment of local malaria transmission due to importation in all areas where it has been eliminated.  To strengthen capacity and systems to generate strategic information on HIV, STIs and Hepatitis through biological and behavior surveillance, surveys and research for evidence-based response to the HIV, STIs and Hepatitis epidemic.  To increase access of women and children to health care services for RMNCAH, HIV, TB and malaria, reduced stigma and discrimination and promotion of health lifestyles in the community and in health facilities in underserved areas.  To improve the enabling environment to address enhanced coordination, human rights, positive legal environment, strengthened community systems, increased domestic funding, reduced stigma and discrimination, to address the needs and rights of key populations affected by HIV, STIs and Hepatitis.  To maintain and improve the quality of the National Laboratory Network.  To improve institutional capacity of Civil Society Organizations and private sector for effective implementation of TB, Malaria and HIV.  To ensure high quality pharmaceuticals and health commodities by strengthening the supply chain, procurement, management, Quality Assurance and regulatory systems.  To improve the data quality of the HMIS and strengthen the utilization of data for decision-making at all levels</narrative>
		</description>
		<participating-org ref="47045" type="30" role="1">
			<narrative xml:lang="en">The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
		</participating-org>
		<participating-org ref="47045" type="30" role="1">
			<narrative xml:lang="en">The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
		</participating-org>
		<participating-org type="40" role="2">
			<narrative xml:lang="en">United Nations Development Programme</narrative>
		</participating-org>
		<participating-org type="40" role="3">
			<narrative xml:lang="en">United Nations Development Programme</narrative>
		</participating-org>
		<participating-org type="40" role="4">
			<narrative xml:lang="en">United Nations Development Programme</narrative>
		</participating-org>
		<other-identifier ref="AFG-Z-UNDPP01" type="A1">
			<owner-org ref="47045">
				<narrative xml:lang="en">The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
			</owner-org>
		</other-identifier>
		<activity-status code="4" />
		<activity-date type="1" iso-date="2021-10-01" />
		<activity-date type="2" iso-date="2021-10-01" />
		<activity-date type="3" iso-date="2023-12-31" />
		<contact-info type="1">
			<organisation>
				<narrative xml:lang="en">The Global Fund to Fight AIDS Tuberculosis and Malaria</narrative>
			</organisation>
			<department>
				<narrative xml:lang="en">Communications</narrative>
			</department>
			<person-name>
				<narrative xml:lang="en">Web Team</narrative>
			</person-name>
			<job-title>
				<narrative xml:lang="en"> </narrative>
			</job-title>
			<telephone>+41 58 791 1700</telephone>
			<email>website@theglobalfund.org</email>
			<website>https://www.theglobalfund.org</website>
			<mailing-address>
				<narrative xml:lang="en">The Global Fund to Fight AIDS, Tuberculosis and Malaria, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland</narrative>
			</mailing-address>
		</contact-info>
		<contact-info type="2">
			<organisation>
				<narrative xml:lang="en">The Global Fund to Fight AIDS Tuberculosis and Malaria</narrative>
			</organisation>
			<department>
				<narrative xml:lang="en">Grant Management Division</narrative>
			</department>
			<person-name>
				<narrative xml:lang="en">Olivier, CAVEY</narrative>
			</person-name>
			<job-title>
				<narrative xml:lang="en">Fund Portfolio Manager</narrative>
			</job-title>
			<telephone>+41 58 791 1700</telephone>
			<email>olivier.cavey@theglobalfund.org</email>
			<website>https://www.theglobalfund.org</website>
			<mailing-address>
				<narrative xml:lang="en">The Global Fund to Fight AIDS, Tuberculosis and Malaria, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland</narrative>
			</mailing-address>
		</contact-info>
		<contact-info type="4">
			<organisation>
				<narrative xml:lang="en">The Global Fund to Fight AIDS Tuberculosis and Malaria</narrative>
			</organisation>
			<department>
				<narrative xml:lang="en">Communications</narrative>
			</department>
			<person-name>
				<narrative xml:lang="en">Web Team</narrative>
			</person-name>
			<telephone>+41 58 791 1700</telephone>
			<email>website@theglobalfund.org</email>
			<website>https://www.theglobalfund.org</website>
			<mailing-address>
				<narrative xml:lang="en">The Global Fund to Fight AIDS, Tuberculosis and Malaria, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland</narrative>
			</mailing-address>
		</contact-info>
		<activity-scope code="4" />
		<recipient-country code="AF" percentage="100">
			<narrative xml:lang="en">Afghanistan</narrative>
		</recipient-country>
		<sector vocabulary="1" code="13040" percentage="8">
			<narrative xml:lang="en">HIV</narrative>
		</sector>
		<sector vocabulary="1" code="12262" percentage="13">
			<narrative xml:lang="en">Malaria</narrative>
		</sector>
		<sector vocabulary="1" code="12110" percentage="44">
			<narrative xml:lang="en">Multicomponent</narrative>
		</sector>
		<sector vocabulary="1" code="12110" percentage="18">
			<narrative xml:lang="en">RSSH</narrative>
		</sector>
		<sector vocabulary="1" code="12263" percentage="17">
			<narrative xml:lang="en">Tuberculosis</narrative>
		</sector>
		<country-budget-items vocabulary="4">
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">HIV -&gt; Differentiated HIV Testing Services -&gt; Community-based testing</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="1">
				<description>
					<narrative xml:lang="en">HIV -&gt; Differentiated HIV Testing Services -&gt; Facility-based testing</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">HIV -&gt; Prevention -&gt; Addressing stigma, discrimination and violence</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="2">
				<description>
					<narrative xml:lang="en">HIV -&gt; Prevention -&gt; Behavior change interventions</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="1">
				<description>
					<narrative xml:lang="en">HIV -&gt; Prevention -&gt; Needle and syringe programs</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="2">
				<description>
					<narrative xml:lang="en">HIV -&gt; Prevention -&gt; Opioid substitution therapy and other medically assisted drug dependence treatment</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="1">
				<description>
					<narrative xml:lang="en">HIV -&gt; Treatment, care and support -&gt; Differentiated ART service delivery and HIV care</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="1">
				<description>
					<narrative xml:lang="en">HIV -&gt; Treatment, care and support -&gt; Prevention and management of co-infections and co-morbidities (Treatment, care and support)</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">Malaria -&gt; Case management -&gt; Epidemic preparedness</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="1">
				<description>
					<narrative xml:lang="en">Malaria -&gt; Case management -&gt; Facility-based treatment</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">Malaria -&gt; Case management -&gt; IEC/BCC (Case management)</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="1">
				<description>
					<narrative xml:lang="en">Malaria -&gt; Case management -&gt; Integrated community case management (iCCM)</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">Malaria -&gt; Case management -&gt; Private sector case management</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">Malaria -&gt; Case management -&gt; Therapeutic efficacy surveillance</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">Malaria -&gt; Vector control -&gt; Entomological monitoring</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">Malaria -&gt; Vector control -&gt; Indoor residual spraying (IRS)</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="1">
				<description>
					<narrative xml:lang="en">Malaria -&gt; Vector control -&gt; Long-lasting insecticidal nets (LLIN) - Continuous distribution - ANC</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="9">
				<description>
					<narrative xml:lang="en">Malaria -&gt; Vector control -&gt; Long-lasting insecticidal nets (LLIN) - Mass campaign - Universal</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="7">
				<description>
					<narrative xml:lang="en">Multicomponent -&gt; COVID-19 -&gt; Case management, clinical operations and therapeutics</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="1">
				<description>
					<narrative xml:lang="en">Multicomponent -&gt; COVID-19 -&gt; Country-level coordination and planning</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="2">
				<description>
					<narrative xml:lang="en">Multicomponent -&gt; COVID-19 -&gt; COVID diagnostics and testing</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">Multicomponent -&gt; COVID-19 -&gt; COVID-19 control and containment including health systems strengthening</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">Multicomponent -&gt; COVID-19 -&gt; COVID-19 CSS: Community-led advocacy and research</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="2">
				<description>
					<narrative xml:lang="en">Multicomponent -&gt; COVID-19 -&gt; Health products and waste management systems</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">Multicomponent -&gt; COVID-19 -&gt; Infection prevention and control, and protection of the health workforce</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="4">
				<description>
					<narrative xml:lang="en">Multicomponent -&gt; COVID-19 -&gt; Laboratory systems</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="1">
				<description>
					<narrative xml:lang="en">Multicomponent -&gt; COVID-19 -&gt; Mitigation for HIV programs</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">Multicomponent -&gt; COVID-19 -&gt; Mitigation for Malaria programs</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">Multicomponent -&gt; COVID-19 -&gt; Mitigation for TB programs</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">Multicomponent -&gt; COVID-19 -&gt; RSSH/PP: Community health workers: Integrated supportive supervision</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="1">
				<description>
					<narrative xml:lang="en">Multicomponent -&gt; COVID-19 -&gt; Surveillance systems</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="1">
				<description>
					<narrative xml:lang="en">Multicomponent -&gt; COVID-19 -&gt; Surveillance: Epidemiological investigation and contact tracing</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="3">
				<description>
					<narrative xml:lang="en">Multicomponent -&gt; Program management -&gt; Coordination and management of national disease control programs</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="23">
				<description>
					<narrative xml:lang="en">Multicomponent -&gt; Program management -&gt; Grant management</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">RSSH -&gt; RSSH: Community systems strengthening -&gt; Community-based monitoring</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">RSSH -&gt; RSSH: Community systems strengthening -&gt; Institutional capacity building, planning and leadership development</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">RSSH -&gt; RSSH: Health management information systems and M&amp;E -&gt; Analysis, evaluations, reviews and transparency</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">RSSH -&gt; RSSH: Health management information systems and M&amp;E -&gt; Program and data quality</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">RSSH -&gt; RSSH: Health products management systems -&gt; Procurement capacity</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">RSSH -&gt; RSSH: Health products management systems -&gt; Regulatory/quality assurance support</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">RSSH -&gt; RSSH: Health products management systems -&gt; Storage and distribution capacity</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="14">
				<description>
					<narrative xml:lang="en">RSSH -&gt; RSSH: Health sector governance and planning -&gt; National health sector strategies and financing</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">RSSH -&gt; RSSH: Human resources for health, including community health workers -&gt; Community health workers: Education and production</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">RSSH -&gt; RSSH: Human resources for health, including community health workers -&gt; HRH policy and governance</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">RSSH -&gt; RSSH: Human resources for health, including community health workers -&gt; In-service training (excluding community health workers)</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">RSSH -&gt; RSSH: Integrated service delivery and quality improvement -&gt; Quality of care</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="1">
				<description>
					<narrative xml:lang="en">RSSH -&gt; RSSH: Integrated service delivery and quality improvement -&gt; Service delivery infrastructure</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="1">
				<description>
					<narrative xml:lang="en">RSSH -&gt; RSSH: Integrated service delivery and quality improvement -&gt; Service organization and facility management</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">RSSH -&gt; RSSH: Laboratory systems -&gt; Information systems and integrated specimen transport networks</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">RSSH -&gt; RSSH: Laboratory systems -&gt; Infrastructure and equipment management systems</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">RSSH -&gt; RSSH: Laboratory systems -&gt; National laboratory governance and management structures</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">RSSH -&gt; RSSH: Laboratory systems -&gt; Quality management systems and accreditation</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="1">
				<description>
					<narrative xml:lang="en">RSSH -&gt; RSSH: Monitoring and evaluation systems -&gt; Routine reporting</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">RSSH -&gt; RSSH: Monitoring and evaluation systems -&gt; Surveys</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">Tuberculosis -&gt; MDR-TB -&gt; Case detection and diagnosis (MDR-TB)</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">Tuberculosis -&gt; MDR-TB -&gt; Community MDR-TB care delivery</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="1">
				<description>
					<narrative xml:lang="en">Tuberculosis -&gt; MDR-TB -&gt; Treatment (MDR-TB)</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">Tuberculosis -&gt; Removing human rights and gender related barriers to TB services -&gt; Community mobilization and advocacy (TB)</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="8">
				<description>
					<narrative xml:lang="en">Tuberculosis -&gt; TB care and prevention -&gt; Case detection and diagnosis (TB care and prevention)</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="1">
				<description>
					<narrative xml:lang="en">Tuberculosis -&gt; TB care and prevention -&gt; Collaborative activities with other programs and sectors (TB care and prevention)</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">Tuberculosis -&gt; TB care and prevention -&gt; Community TB care delivery</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">Tuberculosis -&gt; TB care and prevention -&gt; Engaging all care providers (TB care and prevention)</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">Tuberculosis -&gt; TB care and prevention -&gt; Key Populations (TB care and prevention) - Children</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="1">
				<description>
					<narrative xml:lang="en">Tuberculosis -&gt; TB care and prevention -&gt; Key populations (TB care and prevention) - Mobile populations: refugees, migrants and internally displaced people</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="0">
				<description>
					<narrative xml:lang="en">Tuberculosis -&gt; TB care and prevention -&gt; Key populations (TB care and prevention) - Prisoners</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="1">
				<description>
					<narrative xml:lang="en">Tuberculosis -&gt; TB care and prevention -&gt; Prevention (TB care and prevention)</narrative>
				</description>
			</budget-item>
			<budget-item code="5.1.1" percentage="6">
				<description>
					<narrative xml:lang="en">Tuberculosis -&gt; TB care and prevention -&gt; Treatment (TB care and prevention)</narrative>
				</description>
			</budget-item>
		</country-budget-items>
		<collaboration-type code="1" />
		<default-flow-type code="10" />
		<default-finance-type code="110" />
		<default-aid-type code="C01" />
		<default-tied-status code="5" />
		<budget type="2" status="2">
			<period-start iso-date="2022-01-01" />
			<period-end iso-date="2022-12-31" />
			<value currency="USD" value-date="2021-10-01">23264145.98</value>
		</budget>
		<budget type="2" status="2">
			<period-start iso-date="2023-01-01" />
			<period-end iso-date="2023-12-31" />
			<value currency="USD" value-date="2021-10-01">30850119.54</value>
		</budget>
		<budget type="2" status="2">
			<period-start iso-date="2025-01-01" />
			<period-end iso-date="2025-12-31" />
			<value currency="USD" value-date="2021-10-01">3755330.15</value>
		</budget>
		<budget type="2" status="2">
			<period-start iso-date="2021-01-01" />
			<period-end iso-date="2021-12-31" />
			<value currency="USD" value-date="2021-10-01">17882933.37</value>
		</budget>
		<budget type="2" status="2">
			<period-start iso-date="2024-01-01" />
			<period-end iso-date="2024-12-31" />
			<value currency="USD" value-date="2021-10-01">2474247.92</value>
		</budget>
		<transaction ref="10990348-bbc8-47eb-bec8-efa418681b4d">
			<transaction-type code="2" />
			<transaction-date iso-date="2023-10-03" />
			<value currency="USD" value-date="2023-10-03">25000.00</value>
			<description>
				<narrative xml:lang="en">Global Fund Commitment to AFG-Z-UNDPP01.</narrative>
			</description>
			<provider-org type="40">
				<narrative xml:lang="en">Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
			</provider-org>
			<receiver-org>
				<narrative xml:lang="en">United Nations Development Programme (UNDP Afghanistan)</narrative>
			</receiver-org>
			<aid-type code="C01" />
			<tied-status code="5" />
		</transaction>
		<transaction ref="3ac9ec5e-5059-424d-b1ee-e23acbdebf71">
			<transaction-type code="2" />
			<transaction-date iso-date="2022-01-13" />
			<value currency="USD" value-date="2022-01-13">-19876409.41</value>
			<description>
				<narrative xml:lang="en">Global Fund Commitment to AFG-Z-UNDPP01.</narrative>
			</description>
			<provider-org type="40">
				<narrative xml:lang="en">Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
			</provider-org>
			<receiver-org>
				<narrative xml:lang="en">United Nations Development Programme (UNDP Afghanistan)</narrative>
			</receiver-org>
			<aid-type code="C01" />
			<tied-status code="5" />
		</transaction>
		<transaction ref="d49b88bf-c97e-4c62-8fcb-04813903f718">
			<transaction-type code="2" />
			<transaction-date iso-date="2025-11-10" />
			<value currency="USD" value-date="2025-11-10">-2643931.00</value>
			<description>
				<narrative xml:lang="en">Global Fund Commitment to AFG-Z-UNDPP01.</narrative>
			</description>
			<provider-org type="40">
				<narrative xml:lang="en">Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
			</provider-org>
			<receiver-org>
				<narrative xml:lang="en">United Nations Development Programme (UNDP Afghanistan)</narrative>
			</receiver-org>
			<aid-type code="C01" />
			<tied-status code="5" />
		</transaction>
		<transaction ref="f62abab3-4705-4435-b50b-181be212cd3f">
			<transaction-type code="2" />
			<transaction-date iso-date="2023-03-07" />
			<value currency="USD" value-date="2023-03-07">0.00</value>
			<description>
				<narrative xml:lang="en">Global Fund Commitment to AFG-Z-UNDPP01.</narrative>
			</description>
			<provider-org type="40">
				<narrative xml:lang="en">Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
			</provider-org>
			<receiver-org>
				<narrative xml:lang="en">United Nations Development Programme (UNDP Afghanistan)</narrative>
			</receiver-org>
			<aid-type code="C01" />
			<tied-status code="5" />
		</transaction>
		<transaction ref="87417bee-000c-458d-955c-bbe0c0c02b3a">
			<transaction-type code="2" />
			<transaction-date iso-date="2023-03-07" />
			<value currency="USD" value-date="2023-03-07">-14893470.00</value>
			<description>
				<narrative xml:lang="en">Global Fund Commitment to AFG-Z-UNDPP01.</narrative>
			</description>
			<provider-org type="40">
				<narrative xml:lang="en">Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
			</provider-org>
			<receiver-org>
				<narrative xml:lang="en">United Nations Development Programme (UNDP Afghanistan)</narrative>
			</receiver-org>
			<aid-type code="C01" />
			<tied-status code="5" />
		</transaction>
		<transaction ref="6cc3cfd3-533b-4782-8666-e854ec35ee04">
			<transaction-type code="2" />
			<transaction-date iso-date="2021-12-20" />
			<value currency="USD" value-date="2021-12-20">54192116.41</value>
			<description>
				<narrative xml:lang="en">Global Fund Commitment to AFG-Z-UNDPP01.</narrative>
			</description>
			<provider-org type="40">
				<narrative xml:lang="en">Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
			</provider-org>
			<receiver-org>
				<narrative xml:lang="en">United Nations Development Programme (UNDP Afghanistan)</narrative>
			</receiver-org>
			<aid-type code="C01" />
			<tied-status code="5" />
		</transaction>
		<transaction ref="5eb98b09-28eb-43f2-b197-a0c2a36f63e1">
			<transaction-type code="2" />
			<transaction-date iso-date="2024-09-30" />
			<value currency="USD" value-date="2024-09-30">-6615.04</value>
			<description>
				<narrative xml:lang="en">Global Fund Commitment to AFG-Z-UNDPP01.</narrative>
			</description>
			<provider-org type="40">
				<narrative xml:lang="en">Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
			</provider-org>
			<receiver-org>
				<narrative xml:lang="en">United Nations Development Programme (UNDP Afghanistan)</narrative>
			</receiver-org>
			<aid-type code="C01" />
			<tied-status code="5" />
		</transaction>
		<transaction ref="601f2857-6f92-4611-a7b2-f9fdd1b59923">
			<transaction-type code="2" />
			<transaction-date iso-date="2023-07-08" />
			<value currency="USD" value-date="2023-07-08">14818471.00</value>
			<description>
				<narrative xml:lang="en">Global Fund Commitment to AFG-Z-UNDPP01.</narrative>
			</description>
			<provider-org type="40">
				<narrative xml:lang="en">Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
			</provider-org>
			<receiver-org>
				<narrative xml:lang="en">United Nations Development Programme (UNDP Afghanistan)</narrative>
			</receiver-org>
			<aid-type code="C01" />
			<tied-status code="5" />
		</transaction>
		<transaction ref="24e73eca-048f-4fd3-b0a8-a2060e16050e">
			<transaction-type code="2" />
			<transaction-date iso-date="2022-01-13" />
			<value currency="USD" value-date="2022-01-13">14893470.00</value>
			<description>
				<narrative xml:lang="en">Global Fund Commitment to AFG-Z-UNDPP01.</narrative>
			</description>
			<provider-org type="40">
				<narrative xml:lang="en">Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
			</provider-org>
			<receiver-org>
				<narrative xml:lang="en">United Nations Development Programme (UNDP Afghanistan)</narrative>
			</receiver-org>
			<aid-type code="C01" />
			<tied-status code="5" />
		</transaction>
		<transaction ref="2ed6c46b-e8c0-4f9c-8c62-24114a2be5db">
			<transaction-type code="7" />
			<transaction-date iso-date="2025-11-11" />
			<value currency="USD" value-date="2025-11-11">-2643931.00</value>
			<description>
				<narrative xml:lang="en">Global Fund disbursement to AFG-Z-UNDPP01.</narrative>
			</description>
			<provider-org>
				<narrative xml:lang="en">United Nations Development Programme (UNDP Afghanistan)</narrative>
			</provider-org>
			<receiver-org type="40">
				<narrative xml:lang="en">The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
			</receiver-org>
			<aid-type code="C01" />
			<tied-status code="5" />
		</transaction>
		<transaction ref="154db9a7-155c-44d0-b462-7edebc0c244d">
			<transaction-type code="3" />
			<transaction-date iso-date="2023-07-13" />
			<value currency="USD" value-date="2023-07-13">10354829.25</value>
			<description>
				<narrative xml:lang="en">Global Fund disbursement to AFG-Z-UNDPP01.</narrative>
			</description>
			<provider-org type="40">
				<narrative xml:lang="en">Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
			</provider-org>
			<receiver-org>
				<narrative xml:lang="en">United Nations Development Programme (UNDP Afghanistan)</narrative>
			</receiver-org>
			<aid-type code="C01" />
			<tied-status code="5" />
		</transaction>
		<transaction ref="d5ae6422-4325-47fa-ba6b-380a8f4c6a29">
			<transaction-type code="3" />
			<transaction-date iso-date="2023-10-24" />
			<value currency="USD" value-date="2023-10-24">991420.00</value>
			<description>
				<narrative xml:lang="en">Global Fund disbursement to AFG-Z-UNDPP01.</narrative>
			</description>
			<provider-org type="40">
				<narrative xml:lang="en">Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
			</provider-org>
			<receiver-org>
				<narrative xml:lang="en">United Nations Development Programme (UNDP Afghanistan)</narrative>
			</receiver-org>
			<aid-type code="C01" />
			<tied-status code="5" />
		</transaction>
		<transaction ref="44585e0e-4ec2-4ca7-b02e-652a1fb11516">
			<transaction-type code="3" />
			<transaction-date iso-date="2022-01-06" />
			<value currency="USD" value-date="2022-01-06">34315707.00</value>
			<description>
				<narrative xml:lang="en">Global Fund disbursement to AFG-Z-UNDPP01.</narrative>
			</description>
			<provider-org type="40">
				<narrative xml:lang="en">Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
			</provider-org>
			<receiver-org>
				<narrative xml:lang="en">United Nations Development Programme (UNDP Afghanistan)</narrative>
			</receiver-org>
			<aid-type code="C01" />
			<tied-status code="5" />
		</transaction>
		<transaction ref="90d213fe-c19b-4cfb-9efd-4569194d2aba">
			<transaction-type code="3" />
			<transaction-date iso-date="2023-11-28" />
			<value currency="USD" value-date="2023-11-28">638818.75</value>
			<description>
				<narrative xml:lang="en">Global Fund disbursement to AFG-Z-UNDPP01.</narrative>
			</description>
			<provider-org type="40">
				<narrative xml:lang="en">Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
			</provider-org>
			<receiver-org>
				<narrative xml:lang="en">United Nations Development Programme (UNDP Afghanistan)</narrative>
			</receiver-org>
			<aid-type code="C01" />
			<tied-status code="5" />
		</transaction>
		<transaction ref="398409ec-311d-46b1-a47a-4891e4fddc1f">
			<transaction-type code="3" />
			<transaction-date iso-date="2025-08-01" />
			<value currency="USD" value-date="2025-08-01">680016.00</value>
			<description>
				<narrative xml:lang="en">Global Fund disbursement to AFG-Z-UNDPP01.</narrative>
			</description>
			<provider-org type="40">
				<narrative xml:lang="en">Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
			</provider-org>
			<receiver-org>
				<narrative xml:lang="en">United Nations Development Programme (UNDP Afghanistan)</narrative>
			</receiver-org>
			<aid-type code="C01" />
			<tied-status code="5" />
		</transaction>
		<transaction ref="48223549-4f90-45ca-acd4-345cdf12ca16">
			<transaction-type code="3" />
			<transaction-date iso-date="2025-07-01" />
			<value currency="USD" value-date="2025-07-01">2153387.00</value>
			<description>
				<narrative xml:lang="en">Global Fund disbursement to AFG-Z-UNDPP01.</narrative>
			</description>
			<provider-org type="40">
				<narrative xml:lang="en">Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
			</provider-org>
			<receiver-org>
				<narrative xml:lang="en">United Nations Development Programme (UNDP Afghanistan)</narrative>
			</receiver-org>
			<aid-type code="C01" />
			<tied-status code="5" />
		</transaction>
		<transaction ref="7b333109-9b6c-4f83-a6e1-b2e6362cf73f">
			<transaction-type code="7" />
			<transaction-date iso-date="2024-10-01" />
			<value currency="USD" value-date="2024-10-01">-6615.04</value>
			<description>
				<narrative xml:lang="en">Global Fund disbursement to AFG-Z-UNDPP01.</narrative>
			</description>
			<provider-org>
				<narrative xml:lang="en">United Nations Development Programme (UNDP Afghanistan)</narrative>
			</provider-org>
			<receiver-org type="40">
				<narrative xml:lang="en">The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
			</receiver-org>
			<aid-type code="C01" />
			<tied-status code="5" />
		</transaction>
		<transaction ref="aa46ff02-16d1-4c4e-84ae-625b6c289ed9">
			<transaction-type code="3" />
			<transaction-date iso-date="2024-01-29" />
			<value currency="USD" value-date="2024-01-29">25000.00</value>
			<description>
				<narrative xml:lang="en">Global Fund disbursement to AFG-Z-UNDPP01.</narrative>
			</description>
			<provider-org type="40">
				<narrative xml:lang="en">Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
			</provider-org>
			<receiver-org>
				<narrative xml:lang="en">United Nations Development Programme (UNDP Afghanistan)</narrative>
			</receiver-org>
			<aid-type code="C01" />
			<tied-status code="5" />
		</transaction>
		<document-link url="https://data.theglobalfund.org/grant/AFG-Z-UNDP" format="text/html">
			<title>
				<narrative xml:lang="en">Grant page on the data portal of the Global Fund.</narrative>
			</title>
			<description>
				<narrative xml:lang="en">An overview of a grant over it's lifetime.</narrative>
			</description>
			<category code="A12" />
			<category code="A02" />
			<category code="A01" />
			<category code="A07" />
			<category code="A05" />
			<category code="A08" />
			<document-date iso-date="2026-02-14" />
		</document-link>
		<document-link url="https://www.theglobalfund.org/media/13342/core_grantregulationsversiontwo_regulations_en.pdf" format="application/pdf">
			<title>
				<narrative xml:lang="en">Grant terms and conditions.</narrative>
			</title>
			<description>
				<narrative xml:lang="en">General terms and conditions which apply to Global Fund grants.</narrative>
			</description>
			<category code="A04" />
			<document-date iso-date="2026-02-14" />
		</document-link>
		<result type="1" aggregation-status="false">
			<title>
				<narrative xml:lang="en">Coverage / Output indicators targets and results for AFG-Z-UNDPP01</narrative>
			</title>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Percentage of TB patients with DST result for at least Rifampicin among the total number of notified (new and retreatment) cases in the same year</narrative>
				</title>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-06-30" />
					<target value="50.00" />
					<actual value="44.70" />
				</period>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="50.00" />
					<actual value="50.50" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-06-30" />
					<target value="41.00" />
					<actual value="43.30" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-12-31" />
					<target value="41.00" />
					<actual value="43.80" />
				</period>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="36.00" />
					<actual value="35.20" />
				</period>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="41.00" />
					<actual value="44.30" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-12-31" />
					<target value="50.00" />
					<actual value="47.60" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Percentage of individuals receiving Opioid Substitution Therapy who received treatment for at least 6 months</narrative>
				</title>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-06-30" />
					<target value="79.80" />
					<actual value="61.00" />
				</period>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="75.14" />
					<actual value="82.60" />
				</period>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="80.13" />
					<actual value="62.10" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-06-30" />
					<target value="77.30" />
					<actual value="57.10" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-12-31" />
					<target value="77.60" />
					<actual value="83.50" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-12-31" />
					<target value="80.10" />
					<actual value="62.10" />
				</period>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="77.64" />
					<actual value="83.50" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Percentage of PLHIV on ART who initiated TB preventive therapy among those eligible during the reporting period</narrative>
				</title>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="100.00" />
					<actual value="27.10" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-06-30" />
					<target value="100.00" />
					<actual value="43.50" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-12-31" />
					<target value="100.00" />
					<actual value="38.90" />
				</period>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="100.00" />
					<actual value="28.40" />
				</period>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="100.00" />
					<actual value="32.50" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-06-30" />
					<target value="100.00" />
					<actual value="24.50" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-12-31" />
					<target value="100.00" />
					<actual value="25.70" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Percentage of people on ART among all people living with HIV at the end of the reporting period</narrative>
				</title>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="20.00" />
					<actual value="12.80" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-06-30" />
					<target value="20.65" />
					<actual value="11.60" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-06-30" />
					<target value="23.31" />
					<actual value="9.30" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-12-31" />
					<target value="25.40" />
					<actual value="9.90" />
				</period>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="25.43" />
					<actual value="9.90" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-12-31" />
					<target value="22.50" />
					<actual value="12.10" />
				</period>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="22.53" />
					<actual value="12.10" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Proportion of malaria cases (presumed and confirmed) that received first line antimalarial treatment at private sector sites</narrative>
				</title>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="96.00" />
					<actual value="99.90" />
				</period>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="96.98" />
					<actual value="96.80" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-06-30" />
					<target value="97.02" />
					<actual value="100.00" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-12-31" />
					<target value="96.00" />
					<actual value="100.00" />
				</period>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="95.98" />
					<actual value="100.00" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-06-30" />
					<target value="95.98" />
					<actual value="100.00" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-12-31" />
					<target value="97.00" />
					<actual value="97.50" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">LAB-Other3: Percentage of provincial laboratories showing adequate performance in external quality assurance among the total number of laboratories that undertake bacteriology services during the reporting period</narrative>
				</title>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="80.00" />
					<actual value="81.20" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-12-31" />
					<target value="85.00" />
					<actual value="84.80" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-06-30" />
					<target value="85.00" />
					<actual value="87.50" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-12-31" />
					<target value="82.40" />
					<actual value="40.60" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-06-30" />
					<target value="82.35" />
					<actual value="25.00" />
				</period>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="85.00" />
					<actual value="82.40" />
				</period>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="82.35" />
					<actual value="56.20" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Treatment success rate- all forms: Percentage of TB cases, all forms, bacteriologically confirmed plus clinically diagnosed, successfully treated (cured plus treatment completed) among all TB cases registered for treatment during a specified period, new and relapse cases</narrative>
				</title>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="91.04" />
					<actual value="94.60" />
				</period>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="91.04" />
					<actual value="93.20" />
				</period>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="91.04" />
					<actual value="94.70" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-12-31" />
					<target value="91.00" />
					<actual value="93.20" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-12-31" />
					<target value="91.00" />
					<actual value="94.20" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-06-30" />
					<target value="91.04" />
					<actual value="93.80" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Percentage of people who inject drugs that have received an HIV test during the reporting period and know their results</narrative>
				</title>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="57.47" />
					<actual value="26.30" />
				</period>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="62.31" />
					<actual value="35.70" />
				</period>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="52.62" />
					<actual value="23.90" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-12-31" />
					<target value="57.50" />
					<actual value="26.30" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-12-31" />
					<target value="62.30" />
					<actual value="35.70" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-06-30" />
					<target value="59.89" />
					<actual value="32.50" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-06-30" />
					<target value="55.04" />
					<actual value="25.50" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Proportion of suspected malaria cases that receive a parasitological test at public sector health facilities</narrative>
				</title>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-12-31" />
					<target value="99.00" />
					<actual value="100.00" />
				</period>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="99.00" />
					<actual value="100.00" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-06-30" />
					<target value="99.00" />
					<actual value="100.00" />
				</period>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="99.00" />
					<actual value="99.90" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-12-31" />
					<target value="99.00" />
					<actual value="99.90" />
				</period>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="99.00" />
					<actual value="100.00" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-06-30" />
					<target value="99.00" />
					<actual value="100.00" />
				</period>
			</indicator>
			<indicator measure="1" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Number of people in prisons and other closed settings reached with HIV prevention programs - defined package of services</narrative>
				</title>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="13193" />
					<actual value="8459" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-06-30" />
					<target value="15148" />
					<actual value="7494" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-12-31" />
					<target value="14393" />
					<actual value="12587" />
				</period>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="16792" />
					<actual value="15179" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-06-30" />
					<target value="13886" />
					<actual value="7159" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-12-31" />
					<target value="16792" />
					<actual value="15179" />
				</period>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="14393" />
					<actual value="12587" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Percentage of people who inject drugs reached with HIV prevention programs - defined package of services</narrative>
				</title>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-12-31" />
					<target value="63.80" />
					<actual value="40.60" />
				</period>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="63.85" />
					<actual value="40.60" />
				</period>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="70.00" />
					<actual value="70.60" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-06-30" />
					<target value="61.16" />
					<actual value="30.40" />
				</period>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="58.47" />
					<actual value="39.40" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-12-31" />
					<target value="70.00" />
					<actual value="70.60" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-06-30" />
					<target value="66.54" />
					<actual value="59.30" />
				</period>
			</indicator>
			<indicator measure="1" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Number of needles and syringes distributed per person who injects drugs per year by needle and syringe programs</narrative>
				</title>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="200" />
					<actual value="225" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-12-31" />
					<target value="200" />
					<actual value="225" />
				</period>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="360" />
					<actual value="57" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-12-31" />
					<target value="200" />
					<actual value="152" />
				</period>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="200" />
					<actual value="152" />
				</period>
			</indicator>
			<indicator measure="1" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Number of long-lasting insecticidal nets distributed to at-risk populations through mass campaigns</narrative>
				</title>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="1023879.68" />
					<actual value="663230" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-12-31" />
					<target value="2047759.4" />
					<actual value="1950586" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-06-30" />
					<target value="1023879.68" />
					<actual value="1287356" />
				</period>
			</indicator>
			<indicator measure="1" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Number of notified TB cases (all forms) contributed by non-national TB program providers - community referrals</narrative>
				</title>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="4629" />
					<actual value="3353" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-06-30" />
					<target value="5807" />
					<actual value="4517" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-12-31" />
					<target value="11614" />
					<actual value="8857" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-12-31" />
					<target value="10369" />
					<actual value="7570" />
				</period>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="5185" />
					<actual value="3539" />
				</period>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="5807" />
					<actual value="4340" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-06-30" />
					<target value="5184" />
					<actual value="4031" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Percentage of HIV-positive new and relapse TB patients on ART during TB treatment</narrative>
				</title>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-12-31" />
					<target value="80.00" />
					<actual value="100.00" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-12-31" />
					<target value="90.00" />
					<actual value="94.10" />
				</period>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="90.00" />
					<actual value="100.00" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-06-30" />
					<target value="85.00" />
					<actual value="83.30" />
				</period>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="80.00" />
					<actual value="100.00" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Proportion of suspected malaria cases that receive a parasitological test at private sector sites</narrative>
				</title>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="99.00" />
					<actual value="100.00" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-06-30" />
					<target value="99.00" />
					<actual value="100.00" />
				</period>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="99.00" />
					<actual value="100.00" />
				</period>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="99.00" />
					<actual value="100.00" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-12-31" />
					<target value="99.00" />
					<actual value="100.00" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-06-30" />
					<target value="99.00" />
					<actual value="100.00" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-12-31" />
					<target value="99.00" />
					<actual value="100.00" />
				</period>
			</indicator>
			<indicator measure="1" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Number of people in prisons and other closed settings that have received an HIV test during the reporting period and know their results</narrative>
				</title>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-06-30" />
					<target value="13633" />
					<actual value="5818" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-12-31" />
					<target value="12954" />
					<actual value="5204" />
				</period>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="15112" />
					<actual value="6387" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-12-31" />
					<target value="15112" />
					<actual value="6387" />
				</period>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="12954" />
					<actual value="5204" />
				</period>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="11874" />
					<actual value="3302" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-06-30" />
					<target value="12497" />
					<actual value="5653" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">LAB-Other2: Percentage of regional laboratories showing adequate performance in external quality assurance  among the total number of laboratories that undertake available services during the reporting period</narrative>
				</title>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-12-31" />
					<target value="100.00" />
					<actual value="100.00" />
				</period>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="100.00" />
					<actual value="100.00" />
				</period>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="100.00" />
					<actual value="100.00" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-06-30" />
					<target value="100.00" />
					<actual value="100.00" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-12-31" />
					<target value="100.00" />
					<actual value="100.00" />
				</period>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="100.00" />
					<actual value="100.00" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-06-30" />
					<target value="100.00" />
					<actual value="100.00" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Timeliness of facility reporting: Percentage of submitted facility monthly reports (for the reporting period) that are received on time per the national guidelines</narrative>
				</title>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-12-31" />
					<target value="85.00" />
					<actual value="88.20" />
				</period>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="85.00" />
					<actual value="90.10" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-06-30" />
					<target value="90.00" />
					<actual value="84.10" />
				</period>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="92.99" />
					<actual value="82.30" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-06-30" />
					<target value="85.00" />
					<actual value="86.20" />
				</period>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="90.00" />
					<actual value="79.10" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-12-31" />
					<target value="90.00" />
					<actual value="81.60" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Proportion of malaria cases (presumed and confirmed) that received first line antimalarial treatment at public sector health facilities</narrative>
				</title>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-06-30" />
					<target value="99.00" />
					<actual value="99.50" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-12-31" />
					<target value="99.00" />
					<actual value="99.30" />
				</period>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="99.00" />
					<actual value="98.50" />
				</period>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="99.00" />
					<actual value="99.20" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-06-30" />
					<target value="99.00" />
					<actual value="98.50" />
				</period>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="99.00" />
					<actual value="99.60" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-12-31" />
					<target value="99.00" />
					<actual value="98.70" />
				</period>
			</indicator>
			<indicator measure="1" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Number of long-lasting insecticidal nets distributed to targeted risk groups through continuous distribution</narrative>
				</title>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-12-31" />
					<target value="147438.6" />
					<actual value="181295" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-06-30" />
					<target value="73719.34" />
					<actual value="85151" />
				</period>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="72175" />
					<actual value="87297" />
				</period>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="73719.34" />
					<actual value="96144" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-06-30" />
					<target value="75297" />
					<actual value="66411" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-12-31" />
					<target value="150594" />
					<actual value="162063" />
				</period>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="75297" />
					<actual value="95652" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Proportion of malaria cases (presumed and confirmed) that received first line antimalarial treatment in the community</narrative>
				</title>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="96.00" />
					<actual value="96.60" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-12-31" />
					<target value="96.00" />
					<actual value="97.30" />
				</period>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="95.00" />
					<actual value="97.40" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-06-30" />
					<target value="96.00" />
					<actual value="98.80" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-12-31" />
					<target value="95.00" />
					<actual value="97.90" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-06-30" />
					<target value="95.00" />
					<actual value="98.60" />
				</period>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="95.00" />
					<actual value="97.50" />
				</period>
			</indicator>
			<indicator measure="1" aggregation-status="false">
				<title>
					<narrative xml:lang="en">SD-Other2: Number of people receiving services through Public-Private Partnerships (PPPs)</narrative>
				</title>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="18166.99" />
					<actual value="22396" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-12-31" />
					<target value="36334" />
					<actual value="44973" />
				</period>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="16478" />
					<actual value="23962" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-06-30" />
					<target value="17301.9" />
					<actual value="21099" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-12-31" />
					<target value="34603.8" />
					<actual value="45852" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-06-30" />
					<target value="18166.99" />
					<actual value="22577" />
				</period>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="17301.9" />
					<actual value="24753" />
				</period>
			</indicator>
			<indicator measure="1" aggregation-status="false">
				<title>
					<narrative xml:lang="en">SD-Other1: Number of people receiving services through Family Health Houses (FHHs)</narrative>
				</title>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="61202" />
					<actual value="110194" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-06-30" />
					<target value="61201" />
					<actual value="30828" />
				</period>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="58287" />
					<actual value="48803" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-06-30" />
					<target value="64261" />
					<actual value="79057" />
				</period>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="64262" />
					<actual value="63681" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-12-31" />
					<target value="122403" />
					<actual value="141022" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-12-31" />
					<target value="128523" />
					<actual value="142738" />
				</period>
			</indicator>
			<indicator measure="1" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Number of people in contact with TB patients who began preventive therapy</narrative>
				</title>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-06-30" />
					<target value="16731.68" />
					<actual value="17079" />
				</period>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="14939" />
					<actual value="12503" />
				</period>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="16731.68" />
					<actual value="15174" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-12-31" />
					<target value="33463.4" />
					<actual value="32253" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-06-30" />
					<target value="18739.48" />
					<actual value="15638" />
				</period>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="18739.48" />
					<actual value="15877" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-12-31" />
					<target value="37479" />
					<actual value="31515" />
				</period>
			</indicator>
			<indicator measure="1" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Number of cases with RR-TB and/or MDR-TB that began second-line treatment</narrative>
				</title>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-06-30" />
					<target value="754" />
					<actual value="243" />
				</period>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="754" />
					<actual value="257" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-12-31" />
					<target value="1062" />
					<actual value="324" />
				</period>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="531" />
					<actual value="324" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-12-31" />
					<target value="1508" />
					<actual value="500" />
				</period>
			</indicator>
			<indicator measure="1" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Number of TB cases (all forms) notified among key affected populations/ high risk groups (other than prisoners)</narrative>
				</title>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-06-30" />
					<target value="5462" />
					<actual value="4071" />
				</period>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="3553" />
					<actual value="3123" />
				</period>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="5462" />
					<actual value="3243" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-12-31" />
					<target value="10924" />
					<actual value="7314" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-06-30" />
					<target value="4418" />
					<actual value="3672" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-12-31" />
					<target value="8836" />
					<actual value="8454" />
				</period>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="4418" />
					<actual value="4782" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Completeness of facility reporting: Percentage of expected facility monthly reports (for the reporting period) that are actually received</narrative>
				</title>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-12-31" />
					<target value="90.00" />
					<actual value="81.60" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-12-31" />
					<target value="85.00" />
					<actual value="88.20" />
				</period>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="90.00" />
					<actual value="79.10" />
				</period>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="92.99" />
					<actual value="82.30" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-06-30" />
					<target value="85.00" />
					<actual value="86.20" />
				</period>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="85.00" />
					<actual value="90.10" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-06-30" />
					<target value="90.00" />
					<actual value="84.10" />
				</period>
			</indicator>
			<indicator measure="1" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Number of notified cases of all forms of TB (i.e. bacteriologically confirmed + clinically diagnosed), new and relapse cases</narrative>
				</title>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="39502" />
					<actual value="24747" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-12-31" />
					<target value="71040" />
					<actual value="51593" />
				</period>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="31714" />
					<actual value="24134" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-06-30" />
					<target value="35520" />
					<actual value="27349" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-06-30" />
					<target value="39502" />
					<actual value="25029" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-12-31" />
					<target value="79004" />
					<actual value="49776" />
				</period>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="35520" />
					<actual value="24244" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">HTS Other1: Percentage of WHRB hat have received an HIV test during the reporting period and know their results</narrative>
				</title>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="72.01" />
					<actual value="34.20" />
				</period>
			</indicator>
			<indicator measure="1" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Number of TB cases with RR-TB and/or MDR-TB notified</narrative>
				</title>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-06-30" />
					<target value="531" />
					<actual value="303" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-06-30" />
					<target value="754" />
					<actual value="255" />
				</period>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="755" />
					<actual value="257" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-12-31" />
					<target value="1509" />
					<actual value="512" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-12-31" />
					<target value="1062" />
					<actual value="643" />
				</period>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="358" />
					<actual value="225" />
				</period>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="531" />
					<actual value="340" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Percentage of registered new and relapse TB patients with documented HIV status</narrative>
				</title>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="71.03" />
					<actual value="62.10" />
				</period>
			</indicator>
			<indicator measure="1" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Number of notified TB cases (all forms) contributed by non-national TB program providers - private/non-governmental facilities</narrative>
				</title>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-12-31" />
					<target value="11679" />
					<actual value="5291" />
				</period>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="4655" />
					<actual value="2602" />
				</period>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="5214" />
					<actual value="2796" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-06-30" />
					<target value="5214" />
					<actual value="2979" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-06-30" />
					<target value="5839" />
					<actual value="2576" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-12-31" />
					<target value="10428" />
					<actual value="5775" />
				</period>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="5840" />
					<actual value="2715" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Proportion of suspected malaria cases that receive a parasitological test in the community</narrative>
				</title>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-12-31" />
					<target value="99.00" />
					<actual value="100.00" />
				</period>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="99.00" />
					<actual value="100.00" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-06-30" />
					<target value="99.00" />
					<actual value="100.00" />
				</period>
				<period>
					<period-start iso-date="2022-01-01" />
					<period-end iso-date="2022-12-31" />
					<target value="99.00" />
					<actual value="100.00" />
				</period>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="99.00" />
					<actual value="100.00" />
				</period>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="99.00" />
					<actual value="100.00" />
				</period>
				<period>
					<period-start iso-date="2023-01-01" />
					<period-end iso-date="2023-06-30" />
					<target value="99.00" />
					<actual value="99.90" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Percentage of other vulnerable populations that have received an HIV test during the reporting period and know their results</narrative>
				</title>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="72.01" />
					<actual value="18.10" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">KP Other1: Percentage of WHRB reached with HIV prevention programs - defined package of services</narrative>
				</title>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="80.00" />
					<actual value="103.70" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Percentage of other vulnerable populations reached with HIV prevention programs - defined package of services</narrative>
				</title>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="80.01" />
					<actual value="104.10" />
				</period>
			</indicator>
		</result>
		<result type="3" aggregation-status="false">
			<title>
				<narrative xml:lang="en">Impact indicators targets and results for AFG-Z-UNDPP01</narrative>
			</title>
			<indicator measure="1" aggregation-status="false">
				<title>
					<narrative xml:lang="en">TB mortality rate per 100,000 population</narrative>
				</title>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="25" />
					<actual value="27" />
				</period>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="21" />
					<actual value="31" />
				</period>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="17" />
					<actual value="24" />
				</period>
			</indicator>
			<indicator measure="1" aggregation-status="false">
				<title>
					<narrative xml:lang="en">In-patient malaria deaths: rate per 100,000 persons per year</narrative>
				</title>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="0" />
					<actual value="0" />
				</period>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="0" />
					<actual value="0" />
				</period>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="0" />
					<actual value="0" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">RR-TB and/or MDR-TB prevalence among new TB patients: Proportion of new TB patients with RR-TB and/or MDR-TB</narrative>
				</title>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="4.90" />
					<actual value="2.39" />
				</period>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="4.90" />
					<actual value="2.65" />
				</period>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="4.90" />
					<actual value="1.95" />
				</period>
			</indicator>
			<indicator measure="1" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Reported malaria cases (presumed and confirmed)</narrative>
				</title>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="105669" />
					<actual value="86370" />
				</period>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="95205" />
					<actual value="125788" />
				</period>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="84362" />
					<actual value="180718" />
				</period>
			</indicator>
			<indicator measure="1" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Malaria test positivity rate</narrative>
				</title>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="104532" />
					<actual value="86263" />
				</period>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="94068" />
					<actual value="125620" />
				</period>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="83225" />
					<actual value="180045" />
				</period>
			</indicator>
			<indicator measure="1" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Confirmed malaria cases (microscopy or RDT): rate per 1000 persons per year</narrative>
				</title>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="2.8" />
					<actual value="2.31" />
				</period>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="2.47" />
					<actual value="3.29" />
				</period>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="2.14" />
					<actual value="4.6" />
				</period>
			</indicator>
		</result>
		<result type="2" aggregation-status="false">
			<title>
				<narrative xml:lang="en">Outcome indicators targets and results for AFG-Z-UNDPP01</narrative>
			</title>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Treatment success rate of RR-TB and/or MDR-TB: Percentage of patients with RR and/or MDR-TB successfully treated</narrative>
				</title>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="66.00" />
					<actual value="74.14" />
				</period>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="65.00" />
					<actual value="71.21" />
				</period>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="67.00" />
					<actual value="58.61" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">TB treatment coverage: Percentage of patients with new and relapse TB that were notified and treated among the estimated number of incident TB in the same year (all forms of TB - bacteriologically confirmed plus clinically diagnosed</narrative>
				</title>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="84.00" />
					<actual value="58.79" />
				</period>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="92.00" />
					<actual value="67.28" />
				</period>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="100.00" />
					<actual value="67.07" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Percentage of people living with HIV and on ART who are virologically suppressed</narrative>
				</title>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="85.00" />
					<actual value="83.81" />
				</period>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="80.00" />
					<actual value="77.18" />
				</period>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="90.00" />
					<actual value="88.06" />
				</period>
			</indicator>
			<indicator measure="2" aggregation-status="false">
				<title>
					<narrative xml:lang="en">National aggregate HMIS fully deployed and functional: Percentage of HMIS components in place (HIS deployment, completeness, timeliness, and integration of aggregate disease reporting for HIV, TB and malaria indicators)</narrative>
				</title>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="75.00" />
					<actual value="75.00" />
				</period>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="75.00" />
					<actual value="75.00" />
				</period>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="75.00" />
					<actual value="75.00" />
				</period>
			</indicator>
			<indicator measure="1" aggregation-status="false">
				<title>
					<narrative xml:lang="en">Treatment success rate of all forms of TB - bacteriologically confirmed plus clinically diagnosed, new and relapse</narrative>
				</title>
				<period>
					<period-start iso-date="2022-07-01" />
					<period-end iso-date="2022-12-31" />
					<target value="91.04" />
					<actual value="46582" />
				</period>
				<period>
					<period-start iso-date="2021-10-01" />
					<period-end iso-date="2021-12-31" />
					<target value="91.04" />
					<actual value="43421" />
				</period>
				<period>
					<period-start iso-date="2023-07-01" />
					<period-end iso-date="2023-12-31" />
					<target value="91.04" />
					<actual value="48247" />
				</period>
			</indicator>
		</result>
	</iati-activity>
</iati-activities>